NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
Seagen Inc.
Institute of Hematology & Blood Diseases Hospital, China
University of Nebraska
Henan Cancer Hospital
Czech Lymphoma Study Group
Samsung Medical Center
Eisai Inc.
Zhejiang Cancer Hospital
Lymphoma Study Association
Sun Yat-sen University